Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
travoprost
Overview
What is Travoprost Ophthalmic Solution 0.004%?
Travoprost is a clear, colorless to slightly yellow oil that is very soluble in acetonitrile, methanol, octanol, and chloroform. It is practically insoluble in water.
Travoprost Ophthalmic Solution 0.004% is supplied as sterile, buffered aqueous solution of travoprost with a pH of approximately 6.0 and an osmolality of approximately 290 mOsmol/kg.
Travoprost ophthalmic solution contains: travoprost 0.04 mg/mL; benzalkonium chloride 0.15 mg/mL; boric acid, edetate disodium, mannitol, polyoxyl 40 hydrogenated castor oil, tromethamine, sodium hydroxide and/or hydrochloric acid (to adjust pH) and water for injection.
What does Travoprost Ophthalmic Solution 0.004% look like?
What are the available doses of Travoprost Ophthalmic Solution 0.004%?
Solution containing 0.04 mg/mL travoprost ophthalmic solution. ( )
What should I talk to my health care provider before I take Travoprost Ophthalmic Solution 0.004%?
Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use. ( )
How should I use Travoprost Ophthalmic Solution 0.004%?
Travoprost Ophthalmic Solution USP, 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The recommended dosage is one drop in the affected eye(s) once daily in the evening. Travoprost Ophthalmic Solution USP, 0.004% should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect.
Reduction of the intraocular pressure starts approximately 2 hours after the first administration with maximum effect reached after 12 hours.
Travoprost ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
What interacts with Travoprost Ophthalmic Solution 0.004%?
Sorry No Records found
What are the warnings of Travoprost Ophthalmic Solution 0.004%?
Sorry No Records found
What are the precautions of Travoprost Ophthalmic Solution 0.004%?
Sorry No Records found
What are the side effects of Travoprost Ophthalmic Solution 0.004%?
Sorry No records found
What should I look out for while using Travoprost Ophthalmic Solution 0.004%?
None
What might happen if I take too much Travoprost Ophthalmic Solution 0.004%?
Sorry No Records found
How should I store and handle Travoprost Ophthalmic Solution 0.004%?
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). [See USP Controlled Room Temperature.] Do not freeze.Protect from light.Discard unused portion. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). [See USP Controlled Room Temperature.] Do not freeze.Protect from light.Discard unused portion. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). [See USP Controlled Room Temperature.] Do not freeze.Protect from light.Discard unused portion. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). [See USP Controlled Room Temperature.] Do not freeze.Protect from light.Discard unused portion. Travoprost Ophthalmic Solution 0.004% is a sterile, isotonic, buffered, preserved, aqueous solution of travoprost (0.04 mg/mL)Travoprost ophthalmic solution is supplied as a 2.5 mL and a 5 mL solution, each in a 5 mL natural translucent polypropylene dispenser bottle with a natural translucent low density polyethylene dropper tip and a turquoise polyethylene overcap with a tamper evident locking ring.2.5 mL fill NDC 49884-044-485 mL fill NDC 49884-044-63StorageStore at 2º to 25ºC (36º to 77ºF).Travoprost Ophthalmic Solution 0.004% is a sterile, isotonic, buffered, preserved, aqueous solution of travoprost (0.04 mg/mL)Travoprost ophthalmic solution is supplied as a 2.5 mL and a 5 mL solution, each in a 5 mL natural translucent polypropylene dispenser bottle with a natural translucent low density polyethylene dropper tip and a turquoise polyethylene overcap with a tamper evident locking ring.2.5 mL fill NDC 49884-044-485 mL fill NDC 49884-044-63StorageStore at 2º to 25ºC (36º to 77ºF).Travoprost Ophthalmic Solution 0.004% is a sterile, isotonic, buffered, preserved, aqueous solution of travoprost (0.04 mg/mL)Travoprost ophthalmic solution is supplied as a 2.5 mL and a 5 mL solution, each in a 5 mL natural translucent polypropylene dispenser bottle with a natural translucent low density polyethylene dropper tip and a turquoise polyethylene overcap with a tamper evident locking ring.2.5 mL fill NDC 49884-044-485 mL fill NDC 49884-044-63StorageStore at 2º to 25ºC (36º to 77ºF).Travoprost Ophthalmic Solution 0.004% is a sterile, isotonic, buffered, preserved, aqueous solution of travoprost (0.04 mg/mL)Travoprost ophthalmic solution is supplied as a 2.5 mL and a 5 mL solution, each in a 5 mL natural translucent polypropylene dispenser bottle with a natural translucent low density polyethylene dropper tip and a turquoise polyethylene overcap with a tamper evident locking ring.2.5 mL fill NDC 49884-044-485 mL fill NDC 49884-044-63StorageStore at 2º to 25ºC (36º to 77ºF).Travoprost Ophthalmic Solution 0.004% is a sterile, isotonic, buffered, preserved, aqueous solution of travoprost (0.04 mg/mL)Travoprost ophthalmic solution is supplied as a 2.5 mL and a 5 mL solution, each in a 5 mL natural translucent polypropylene dispenser bottle with a natural translucent low density polyethylene dropper tip and a turquoise polyethylene overcap with a tamper evident locking ring.2.5 mL fill NDC 49884-044-485 mL fill NDC 49884-044-63StorageStore at 2º to 25ºC (36º to 77ºF).Travoprost Ophthalmic Solution 0.004% is a sterile, isotonic, buffered, preserved, aqueous solution of travoprost (0.04 mg/mL)Travoprost ophthalmic solution is supplied as a 2.5 mL and a 5 mL solution, each in a 5 mL natural translucent polypropylene dispenser bottle with a natural translucent low density polyethylene dropper tip and a turquoise polyethylene overcap with a tamper evident locking ring.2.5 mL fill NDC 49884-044-485 mL fill NDC 49884-044-63StorageStore at 2º to 25ºC (36º to 77ºF).
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Non-Clinical Toxicology
NoneResults of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose solution.
Travoprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to increase as long as travoprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of travoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long term effects of increased pigmentation are not known.
Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with travoprost ophthalmic solution can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly. (see , ).
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).